The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against Ultragenyx's motion to dismiss, allowing the case to continue.
Target reported a first-quarter FY24 sales decline of 3.1% year-on-year to $24.531 billion, with comparable sales down 3.7%. Adjusted EPS was $2.03, missing the consensus estimate of $2.06. BofA Securities reiterated a Buy rating with a $190 price target. Telsey Advisory Group reiterated an Outperform rating with a $195 price target, highlighting outperformance in beauty and future market share gains.
Siyata Mobile said the Baha Mar resort in Nassau, Bahamas is using hundreds of SD7 handsets and accessories to extend usage of the devices across the property.